Agreements reached under this partnership
Business Alliances- 1
Research topic: Prospective observational study of treatment monitoring through liquid biopsies in patients with solid tumors
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The impact of this matter on our financial results for the fiscal year ending March 2027 is expected to be immaterial.
| Item | Details |
|---|---|
| Name of alliance partner | The University of Tokyo, EIKEN CHEMICAL CO.,LTD. |
| Alliance partner's business activities | The University of Tokyo: Not disclosed, EIKEN CHEMICAL CO.,LTD.: Manufacture, sale, and import and export sale of pharmaceuticals, reagents, medical and scientific instruments, and other products |
| Alliance partner's location | Bunkyo-ku, Tokyo, Chiyoda-ku, Tokyo |
| Alliance partner's capital | EIKEN CHEMICAL CO.,LTD.: ¥6,897.73 million (The University of Tokyo: Not disclosed) |
| Type of alliance | Business Alliances |
| Details of the alliance | Research topic: Prospective observational study of treatment monitoring through liquid biopsies in patients with solid tumors |
| Impact on Business Performance | The impact of this matter on our financial results for the fiscal year ending March 2027 is expected to be immaterial. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To verify the testing performance of the new cancer gene panel being developed by CPM using blood samples from patients with solid tumors, and to evaluate its clinical utility in assessing and predicting the efficacy of drug treatments through repeated testing.